Comparison of icodextrin and glucose solutions for long dwell exchange in peritoneal dialysis: a meta-analysis of randomized controlled trials.
BACKGROUND
Icodextrin is widely used in peritoneal dialysis (PD); however, the safety and efficacy of icodextrin are unclear. In the present study, we performed a systematic review of randomized controlled trials (RCTs) that compared icodextrin and glucose for the once-daily long dwell in PD.


METHODS
Electronic searches were performed in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials to select all eligible studies. Eligible studies, as determined by consensus using predefined criteria, were reviewed, and data were extracted onto a standard form.


RESULTS
In the 9 RCTs that were identified, patients using icodextrin were found to have much greater net ultrafiltration (UF) and a lower incidence of negative net UF compared to patients using 1.5%, 2.5%, and 4.25% glucose solutions. Additionally, icodextrin has a markedly increased UF efficiency ratio and peritoneal clearance of creatinine and urea nitrogen, but residual renal function was not different from patients using glucose solutions for PD. No significant differences were observed between icodextrin and glucose groups with respect to risk of mortality, peritonitis, and total adverse events. Although rashes occurred significantly more often in icodextrin groups, few differences were noted between icodextrin and glucose groups when withdrawal rates secondary to adverse events were compared.


CONCLUSIONS
This meta-analysis suggests that icodextrin provides patients with greater fluid removal and small solute clearance and does not cause any damage to residual renal function. Icodextrin is particularly appropriate for use in patients with high peritoneal transport status.
Department of Nephrology, East Hospital, Tongji University School of Medicine, Shanghai, China.
Hualin
H
Qi
Chen
C
Xu
Haidong
H
Yan
Jun
J
Ma
D001692:Biological Transport; D015314:Dialysis Solutions / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005936:Glucans / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005947:Glucose / Q000008:administration & dosage / Q000493:pharmacokinetics*; D015312:Hemodialysis Solutions; D006801:Humans; D000077607:Icodextrin; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D018384:Oxidative Stress / Q000187:drug effects*; D010530:Peritoneal Dialysis / Q000379:methods*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D015314:Dialysis Solutions; D005936:Glucans; D015312:Hemodialysis Solutions; D000077607:Icodextrin; D005947:Glucose